Trial Profile
An effect of treprostinil on stroke volume index (SVI) and multi-point pulmonary artery pressure-flow (PF) in patients with advanced treatment naive pulmonary arterial hypertension.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Jun 2016
Price :
$35
*
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- 23 Jun 2016 New trial record
- 18 May 2016 Results presented at the 112th International Conference of the American Thoracic Society